Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
10 reports, 4 independent
Updated Aug 7
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 10
- Developments
- 10
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Major pharmaceutical companies, including Pfizer, Amgen, Eli Lilly, and Novo Nordisk, are leading the market in next-generation GLP-1 drugs for weight loss and diabetes.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Eli Lilly and Novo Nordisk both launched oral GLP-1 medications this year, marking a major competitive development in the market.Sub-event
Eli Lilly takes the lead in the GLP-1 weight-loss drug market.1 source
Eli Lilly takes the lead in the competitive GLP-1 weight-loss drug market.1 source
Pfizer and Eli Lilly are competing for market share in the GLP-1 weight-loss sector.1 source
- Novo Nordisk is expanding its market access, with UAE approval preceding UK market entry.Sub-event
- Market projections show the weight loss drug market is expected to reach $150 billion by 2035, driven by competition among major pharmaceutical companies.Sub-event
- Eli Lilly and Novo Nordisk faced market pressure from federal policy, while the CalRx program funded Civica for production runs.Sub-event
- Eli Lilly reported compliance status to HRSA and is scheduled to present data at a meeting in Stockholm.Sub-event
Show 2 earlier steps
Successful FDA and China NMPA approvals for Eli Lilly's drug candidates.1 source
Industry leaders are dominating the branded weight-loss drug market with improved GLP-1 technologies.1 source
Keep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Amgen
American multinational biopharmaceutical company
-
Eli Lilly and Company
American pharmaceutical company
-
Novo Nordisk
Danish pharmaceutical company
Related events
- Eli Lilly, Novo Nordisk, and Merck are currently competing in the highly competitive GLP-1 obesity market.
- GLP-1 drugs are identified as the primary cause of weight loss, accompanied by commentary on the industry's power over regulatory agencies.
- Eli Lilly referred entities to the FDA regarding the GLP-1 market on August 24, 2026.
- Novo Nordisk received approval in China for Wegovy, while Chinese drugmakers are developing their own GLP-1 medicines.
- Morgan Stanley estimates market growth for GLP-1 drugs, noting competition between Eli Lilly and Novo Nordisk.